Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00741780|
Recruitment Status : Completed
First Posted : August 26, 2008
Last Update Posted : March 24, 2015
|Condition or disease||Intervention/treatment|
|Multiple Myeloma Autologous Transplantation||Drug: Placebo Drug: plerixafor Drug: granulocyte colony-stimulating factor (G-CSF)|
|Study Type :||Observational|
|Actual Enrollment :||164 participants|
|Official Title:||Long-term Observational Follow-up Study of a Multicenter, Randomized, Double-blind, Placebo-controlled, Comparative Trial of AMD3100 (240µg/kg) Plus G-CSF (10µg/kg) Versus G-CSF (10µg/kg) Plus Placebo to Mobilize and Collect ≥ 6X 10^6 CD34+ Cells/kg in Multiple Myeloma Patients for Autologous Transplantation|
|Study Start Date :||June 2006|
|Actual Primary Completion Date :||July 2011|
|Actual Study Completion Date :||July 2011|
G-CSF plus plerixafor
Participants in AMD3100-3102 (NCT00103662) who underwent mobilization with granulocyte colony-stimulating factor (G-CSF) and received plerixafor prior to undergoing apheresis.
Other Names:Drug: granulocyte colony-stimulating factor (G-CSF)
G-CSF plus placebo
Participants in AMD3100-3102 (NCT00103662) who underwent mobilization with granulocyte colony-stimulating factor (G-CSF) and received placebo prior to undergoing apheresis.
|Drug: Placebo Drug: granulocyte colony-stimulating factor (G-CSF)|
- Progression-free survival and overall survival of patients treated with at least 1 dose of study treatment (placebo or plerixafor) in protocol AMD3100-3102 (NCT00103662) [ Time Frame: 5 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00741780
|Study Director:||Medical Monitor||Genzyme, a Sanofi Company|